[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365939-105":59,"doc-detail-365939-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-effectiveness-and-harms-of-psa-based-prostate-cancer-screening-a-systematic-review","The Effectiveness and Harms of PSA-Based Prostate Cancer Screening: A Systematic Review","","Prostate cancer’s prevalence is rapidly increasing in Korea, with incidence rates rising by over 13% annually since 2017, underscoring the need for effective early detection strategies. This systematic review evaluates the benefits and harms of PSA-based prostate cancer screening, addressing clinical effectiveness and public health implications. Following PRISMA 2020, studies from 2014–2024 were synthesized using PRISMA-aligned risk-of-bias assessment and narrative synthesis due to heterogeneity.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-effectiveness-and-harms-of-psa-based-prostate-cancer-screening-a-systematic-review/365939/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-effectiveness-and-harms-of-psa-based-prostate-cancer-screening-a-systematic-review/365939.png","ImageObject",300,407,{"name":92,"@type":93},"วิน","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What does the review evaluate about PSA-based prostate cancer screening?","Question",{"text":113,"@type":114},"It evaluates both benefits and harms, focusing on clinical effectiveness and public health implications of PSA-based screening.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What effect does PSA screening have on prostate-cancer-specific mortality?",{"text":118,"@type":114},"PSA screening reduces prostate-cancer-specific mortality by about 20–31% according to multiple randomized controlled trials, particularly among men aged 55–69.",{"name":120,"@type":111,"acceptedAnswer":121},"What harms are highlighted in PSA-based screening?",{"text":122,"@type":114},"The review identifies overdiagnosis, overtreatment, and psychological distress as key potential harms.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},365939,1790375206,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","Systematic Review  \nThe Effectiveness and Harms of PSA-Based Prostate Cancer Screening: A Systematic Review  \nChung-uk Oh 1 and Hyekyung Kang 2, *  \nAcademic Editor: Daniele Giansanti  \nReceived: 6 April 2025  \nRevised: 31 May 2025  \nAccepted: 6 June 2025  \nPublished: 9 June 2025  \nCitation: Oh, C.-u.; Kang, H. The Effectiveness and Harms of PSA-Based Prostate Cancer Screening: A Systematic Review. Healthcare 2025, 13, 1381. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)healthcare13121381  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Nursing, Kangwon National University, Dogye-eup, Samcheok-si 25949, Gangwon-do, Republic of Korea; [ohcu@kangwon.ac.kr](ohcu@kangwon.ac.kr)  \n2 Department of Nursing, Joongbu University, Chubu-myeon, Geumsan-gun 32713, Chungcheongnam-do, Republic of Korea  \n* Correspondence: [kanghk@joongbu.ac.kr](kanghk@joongbu.ac.kr)  \nAbstract: Objectives: Prostate cancer’s prevalence is rapidly increasing in Korea, with incidence rates rising by over 13% annually since 2017 according to the Korea Central Cancer Registry, highlighting the need for effective early detection strategies. This study systematically reviews the benefits and harms of PSA-based prostate cancer screening, focusing on its clinical effectiveness and public health implications. Methods: Following PRISMA 2020 guidelines, we searched five databases (PubMed, Embase, Cochrane Library, Google Scholar, and KMbase) for studies from 2014 to 2024 . The eligible studies included RCTs, cohort studies, meta-analyses, and guidelines. Risk of bias was assessed using the Cochrane tool. We synthesized our findings narratively due to their methodological heterogeneity. Results: Sixteen studies were included. PSA screening reduced prostate-cancer-specific mortality by 20–31%, as reported in multiple randomized controlled trials, such as ERSPC and ProScreen, among men aged 55–69, but showed minimal impact on all-cause mortality. Advanced tools such as MRI and multi-biomarker models, which were implemented in several included studies, enhanced diagnostic accuracy. The potential harms included overdiagnosis, overtreatment, and psychological distress. Community-based education and shared decision-making, inferred from observational and implementation studies, improved participation and equity in screening. Conclusions: PSA-based screening offers modest mortality benefits but carries the risk of overdiagnosis. Precision diagnostics and risk-stratified strategies improve screening outcomes. Public health approaches, particularly those led by nurses and community health workers, are essential to promoting informed, equitable screening decisions.  \nKeywords: prostate cancer screening; PSA; early detection; effectiveness; community health worker  \n1. Introduction  \nProstate cancer remains a major contributor to male cancer mortality on a global scale. The global incidence is projected to rise sharply from 1.4 million cases in 2020 to 2.9 million by 2040 according to GLOBOCAN 2020 estimates [1] . In South Korea, prostate cancer has shown the fastest increase in incidence among all male cancers over the past five years, likely due to a combination of population aging, improved diagnostic access, and heightened public awareness in Korean men [2] . Given that increasing age is a significant risk factor, the country’s rapid demographic aging is expected to further accelerate the domestic burden of prostate cancer [3] . In this context, the necessity of early detection has been emphasized, especially among men aged 50 years and older.  \nAlthough early detection significantly improves survival outcomes, prostate cancer is known to be","cbCait07fdWHDudD","https://ap.wps.com/l/cbCait07fdWHDudD","pdf",892096,16,"English","# Abstract\n# Introduction\n## Epidemiology and need for early detection\n## PSA testing, debates, and guideline differences\n# Methods\n## Search strategy and eligibility criteria\n## Risk of bias assessment\n## Data synthesis approach\n# Results\n## Mortality outcomes and diagnostic accuracy\n## Potential harms\n## Community education and shared decision-making\n# Conclusions","[{\"question\":\"What does the review evaluate about PSA-based prostate cancer screening?\",\"answer\":\"It evaluates both benefits and harms, focusing on clinical effectiveness and public health implications of PSA-based screening.\"},{\"question\":\"What effect does PSA screening have on prostate-cancer-specific mortality?\",\"answer\":\"PSA screening reduces prostate-cancer-specific mortality by about 20–31% according to multiple randomized controlled trials, particularly among men aged 55–69.\"},{\"question\":\"What harms are highlighted in PSA-based screening?\",\"answer\":\"The review identifies overdiagnosis, overtreatment, and psychological distress as key potential harms.\"}]","The Effectiveness and Harms of PSA-Based Prostate Cancer Screening: A Systematic Review | PDF",1790163035,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6bf25521f7da94fe3e580ec2ce15fe2e.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/572aacfc52767094842ffe8776c66ad9.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa370dedbe1628af20149f7bcaf20cc3.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9806f781f1875f56083b3aa0d652f6a5.webp",980,1385]